Cambridge Investment Research Advisors, Inc. Gilead Sciences, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.9 Billion
- Q4 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 152,243 shares of GILD stock, worth $17.1 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
152,243
Previous 135,868
12.05%
Holding current value
$17.1 Million
Previous $11.4 Million
23.46%
% of portfolio
0.05%
Previous 0.04%
Shares
32 transactions
Others Institutions Holding GILD
# of Institutions
2,102Shares Held
986MCall Options Held
8.73MPut Options Held
9.63M-
Black Rock Inc. New York, NY121MShares$13.5 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA116MShares$12.9 Billion0.19% of portfolio
-
Capital World Investors Los Angeles, CA71.7MShares$8.03 Billion1.05% of portfolio
-
State Street Corp Boston, MA60.4MShares$6.77 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA57.9MShares$6.49 Billion1.15% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $140B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...